← Back to patent-cliff list
FT-2109
Tier C — Watch / tradeFT-2109
Forward Therapeutics Inc
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：TNF
Indications (approved)：肠道疾病, Intestinal neoplasm, 结肠疾病, Colorectal cancer, 胃肠道癌症, 胃肠疾病, 消化系统肿瘤, 直肠疾病
Regional status
US
Phase III
2025-12-11
EU
Phase III
2025-12-11
China
Phase III
2025-12-11
Japan
Phase III
2025-12-11
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of FT-2109?
Approved indications include: 肠道疾病, Intestinal neoplasm, 结肠疾病, Colorectal cancer, 胃肠道癌症, 胃肠疾病, 消化系统肿瘤, 直肠疾病.
When does the FT-2109 patent expire?
No public expiry year is available for FT-2109 yet; this page updates once verified.
How do I get a quote for FT-2109 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-29